Litcius/Paper detail

RBMS2 Chemosensitizes Breast Cancer Cells to Doxorubicin by Regulating BMF Expression

Feng Xu, Tian Xia, Qitong Xu, Xu Zhang, Yuzhou Huang, Xi Sun, Liang Shi, Shu‐Feng Zhou, Ji‐Fu Wei, Qiang Ding

2022International Journal of Biological Sciences20 citationsDOIOpen Access PDF

Abstract

. RIP assay and dual-luciferase reporter assay were performed to explore the relationship between RBMS2 and BMF. Our data demonstrated that upregulation of RBMS2 in breast cancer cells could enhance sensitivity to doxorubicin and promote apoptosis in the presence of doxorubicin, while inhibition of RBMS2 showed an opposite trend. Moreover, this chemosensitizing effect of RBMS2 could be reversed by the inhibition of Bcl-2 modifying factor (BMF). RBMS2 positively regulated BMF expression and increased BMF-induced expression of (cleaved) caspase 3, (cleaved) caspase 9 and poly (ADP-Ribose) polymerase (PARP). These results uncovered a novel mechanism for RBMS2 in the sensibilization of doxorubicin, suggesting that RBMS2 may act as a potential therapeutic target for drug-resistant breast cancer.

Topics & Concepts

DoxorubicinCancer researchFlow cytometryBreast cancerApoptosisDownregulation and upregulationIn vivoCytotoxicityChemistryIn vitroCancerBiologyMolecular biologyMedicineChemotherapyInternal medicineBiochemistryGeneBiotechnologyRNA Research and SplicingRNA modifications and cancerRNA and protein synthesis mechanisms
RBMS2 Chemosensitizes Breast Cancer Cells to Doxorubicin by Regulating BMF Expression | Litcius